Development and validation of the Risk of Exacerbation in Severe Asthma (RESA) model.
No Thumbnail Available
Authors
Chen W.
Lee T.Y.
Price D.
Beasley R.
Janson C.
Siyue M.K.
Yadav C.P.
Mullerova H.
Burgel P.R.
Tran T.N.
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND: Severe asthma (SA) is associated with frequent exacerbations and high treatment costs. OBJECTIVE(S): Develop and validate an individualized risk calculator for severe exacerbations in SA, and evaluate its clinical utility for guiding personalized clinical decisions. METHOD(S): Patients with SA were identified from combined data from the International Severe Asthma Registry (2015-2022) and NOVEL observational longiTudinal studY (2016-2023) across 30 countries. The prediction endpoint was the 12-month risk of >=1 or >=2 severe exacerbations. Using expert input and Bayesian network analysis, 11 routinely measured predictors were identified, measured within the past 12 months. A mixed-effects, zero-inflated negative binomial model was developed, adjusting for between-country variability and biologic drop-in effects. Internal-external cross-validation (IECV) was performed using the natural clustering by country-settings. RESULT(S): Data from 9,911 SA patients were used. Essential predictors included age, sex, past 12-month severe exacerbations, asthma control, chronic rhinosinusitis, forced expiratory volume in one second (FEV1) to forced vital capacity ratio, percent predicted FEV1, blood eosinophils, fractional exhaled nitric oxide, long-term oral corticosteroids and macrolide use. The model also adapted setting-specific baseline risks. In the IECV, across broad geographical and healthcare variability, the model showed excellent calibration and informative, generalizable discrimination (pooled AUC of 0.63 [95% CI: 0.60-0.66] for >=1 and 0.68 [95% CI: 0.64-0.72] for >=2 exacerbations). Decision curve analysis showed clear net benefit across risk thresholds. CONCLUSION(S): The Risk of Exacerbation in Severe Asthma (RESA) model quantifies SA exacerbation risk using routinely available predictors and demonstrates potential clinical utility. Copyright © 2026. Published by Elsevier Inc.
Description
Citation
Publisher
License
Journal
The journal of allergy and clinical immunology.In practice